___

• Kaynaklar 1.Cornell S. Comparison of the diabetes guidelines from the ADA/EASDand the AACE/ACE J Am Pharm Assoc (2003). 2017;57(2):261-265. 2.Marathe, P.H., et al,American Diabetes Association Standards of Me-dical Care in Diabetes 2017. Diabetes Care 2017,40(Suppl. 1):66 3.Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, et al. Statementby American Association of Clinical Endocrinologists/ American Col-lege of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus:An algorithm for glycemic control. Endocr Pract 2009;15:540-59. 4.Canadian Diabetes Association. 2008 Clinical Practice Guidelinesfor the Prevention and Management of Diabetes in Canada. Cana-dian J Diabetes 2008;32(Suppl. 1):1-215. 5.National Institute for Health and Clinical Excellence (NICE). Type 2diabetes: the management of type 2 diabetes. 2008. (www.nice. org.uk). 6.Nathan DM, Buse JB, Davidson MB, et al. Medical management ofhyperglycemia in type 2 diabetes -a consensus algorithm for the ini-tiation and adjustment of therapy: a consensus statement of the Ame-rican Diabetes Association and the European Association for the Studyof Diabetes. Diabetes Care 2009;32:193–203. 7.Diabetes Mellitus ve Komplikasyonlarının Tanı,Tedavi ve İzlem Kı-lavuzu-2016 8.Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinicaloutcomes and adverse events associated with glucose-lowering drugsin patients with type 2 diabetes: a meta-analysis. JAMA2016;316:313–324 9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-yearfollow-up of intensive glucose control in type 2 diabetes.N Engl J Med2008;359: 1577–1589 10. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectivenessand safety of medications for type 2 diabetes: an update includingnew drugs and 2-drug combinations. Ann Intern Med2011;154:602–613 11. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes PreventionProgram Research Group.Long-term metformin use and vitamin B12defi- ciency in the Diabetes Prevention Program Outcomes Study.J Clin Endocrinol Metab 2016;101: 1754–1761 12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management ofhyperglycemia in type 2 diabetes, 2015: a patient-centered appro-ach: update to a position statement of the American Diabetes Asso-ciation and the European Association for the Study of Diabetes. Dia-betes Care 2015;38:140–149 13. Chiasson J-L, Josse RG, Hunt JA, et al.The efficacy of acarbose inthe treatment of patients with non-insulin-dependent diabetes mel-litus. A multicenter controlled clinical trial. Ann Intern Med1994;121:928-35. 14. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of ro-siglitazone, metformin, or glyburide monotherapy. N Engl J Med2006;355:2427-43. 15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensi-ve blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65. 16. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-con-trolled clinical trials assessing the efficacy and safety of incretinba-sed medications in patients with type 2 diabetes. Pharmacology2010;86:44-57. 17. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin androsiglitazone combination therapy in patients with type 2 diabetes mel-litus: a randomized controlled trial. JAMA 2000;283:1695-702 18. Diamant M, Nauck MA, Shaginian R, et al.; 4B Study Group. Glu-cagon-like peptide 1 receptor agonist or bolus insulin with optimi-zed basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763–2773 19. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like pepti-de-1 receptor agonist and basal insulin combination treatment forthe management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384: 2228–2234 20. Mathieu C, Storms F, Tits J, Veneman TF, Colin IM. Switching frompremixed insulin to basal-bolus insulin glargine plus rapid-actinginsulin: the ATLANTIC study. Acta Clin Belg 2013; 68:28–33 21. Dieuzeide G, Chuang L-M, Almaghamsi A, Zilov A, Chen J-W, La-valle-Gonzalez FJ. Safety ´ and effectiveness of biphasic insulin as-part 30 in people with type 2 diabetes switching from basal-bolus in-sulin regimens in the A1chieve study. Prim Care Diabetes2014;8:111–117 22. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K.Intensification of insulin therapy with basal-bolus or premixed in-sulin regimens in type 2 diabetes: a systematic review and meta-analy-sis of randomized controlled trials. Endocrine 2016;51:417–428